Corbus Pharmaceuticals (NASDAQ:CRBP) received a $32.00 price target from equities research analysts at Cantor Fitzgerald in a research report issued on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 374.07% from the stock’s previous close.
Other research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. ValuEngine upgraded shares of Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Noble Financial restated a “buy” rating on shares of Corbus Pharmaceuticals in a research report on Friday, December 15th. Finally, Raymond James Financial began coverage on shares of Corbus Pharmaceuticals in a research report on Friday, January 19th. They issued an “outperform” rating and a $24.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $25.75.
Corbus Pharmaceuticals (CRBP) opened at $6.75 on Monday. Corbus Pharmaceuticals has a 52-week low of $5.30 and a 52-week high of $10.50. The stock has a market cap of $362.11, a PE ratio of -10.89 and a beta of 152.04.
Large investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System bought a new position in shares of Corbus Pharmaceuticals in the third quarter valued at $108,000. Yellowstone Partners LLC bought a new position in shares of Corbus Pharmaceuticals in the third quarter valued at $110,000. Aries Wealth Management bought a new position in shares of Corbus Pharmaceuticals in the fourth quarter valued at $153,000. Voya Investment Management LLC bought a new position in shares of Corbus Pharmaceuticals in the second quarter valued at $125,000. Finally, MetLife Investment Advisors LLC bought a new position in shares of Corbus Pharmaceuticals in the fourth quarter valued at $164,000. 38.03% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Corbus Pharmaceuticals (CRBP) Given a $32.00 Price Target by Cantor Fitzgerald Analysts” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.themarketsdaily.com/2018/03/14/corbus-pharmaceuticals-crbp-given-a-32-00-price-target-by-cantor-fitzgerald-analysts.html.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.